MET Kinase Inhibitor Patent US12595245B2 Granted

ChangeBridge: Patent Grants - Organic Chemistry (C07D)

Published April 7th, 2026

Detected April 7th, 2026

Summary

The USPTO granted patent US12595245B2 to Celyn Therapeutics, Inc. covering MET receptor tyrosine kinase inhibitor compounds, pharmaceutical compositions, and methods of use for treating disease. The patent contains 18 claims and is classified under CPC codes C07D 401/12, C07D 215/22, C07D 405/14, and C07D 471/04. This grant establishes enforceable intellectual property rights for the disclosed MET kinase inhibitors.

View original document View source feed page

What changed

USPTO granted patent US12595245B2 to Celyn Therapeutics, Inc., awarding exclusive intellectual property rights for MET receptor tyrosine kinase inhibitor compounds, pharmaceutical compositions, and associated treatment methods. The patent issues from Application No. 18341503, filed June 26, 2023, with 18 claims covering the disclosed chemical compounds and their therapeutic applications.

Pharmaceutical manufacturers and biotechnology companies engaged in MET-targeted oncology or precision medicine development should monitor this patent for freedom-to-operate considerations and potential licensing opportunities. The grant reinforces the commercial viability of the assignees' kinase inhibitor pipeline and provides enforceable IP protection in the competitive MET inhibitor therapeutic space.

What to do next

Monitor for updates

Source document (simplified)

← USPTO Patent Grants

Inhibitors of MET kinase

Grant US12595245B2 Kind: B2 Apr 07, 2026

Assignee

CELYN THERAPEUTICS, INC.

Inventors

Xiaohu S. Ouyang, Toufike Kanouni, John S. Tyhonas, Jason M. Cox, Robert S. Kania

Abstract

Provided herein are inhibitors of MET receptor tyrosine kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said MET kinase inhibitory compounds for the treatment of disease.